FDA labels AbbVie hep C drug Breakthrough

Share this article:

Abbvie and partner Enanta Pharmaceuticals have tucked a Breakthrough Therapy label under their belts. The FDA granted the expedited review status Friday to the experimental hepatitis C treatment that includes protease inhibitor ABT-450 and ombitasvir and dasabuvir, with or without the interferon ribavirin.

The all-oral's progress means the FDA will review the drug within six months, and that AbbVie deposited an additional milestone payment into Enanta's accounts.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.